BioMedical SIG #4

BioMedical SIG #4

Learn about essential IP strategies for healthcare spin-outs, focusing on how tailored approaches for biotech, pharma, and digital health innovations can ensure long-term success.

Book Your Place

This event has now expired

Fourth webinar in the series: From research and innovation to development: how to plan and execute translational projects in life sciences, this edition looks more closely at IP protection strategies for translational research.

It focuses on intellectual property (IP) and spin-out strategies in the human healthcare sector. A well-designed IP strategy, tailored to the type of innovation, is crucial for the long-term success of university spin-outs.

Join experts Sara Holland, Dave Holt, and Elisabeth Downey as they guide you through the key elements of a comprehensive IP strategy, including licences and agreements. They’ll share insights on the essential components of an IP strategy for the healthcare sector and discuss how these components vary based on the type of innovation—whether in biotech, pharma, or digital health—and the intended business model.

Booking Options

  • Are you an ASTP Member?

  • By proceeding with this booking, you are agreeing to allow ASTP to use your image solely for promotional and educational purposes.

Testimonials

testimonial

Organisation and speakers were great, so enthusiastic about their work and very good at transferring their knowledge.

Sarka Bartova

Research Centre Rez, Czech Republic

testimonial

The software training filled in the many blanks and brought my 'fractioned' knowledge in a structured way. Very useful!

Ilse Sienaert

KU Leuven R&D, Belgium

testimonial

The software course has provided invaluable information as our TTO expands to take on software cases.

Tom Withnell

University of Vienna, Austria

testimonial

A must-do for any staff involved in technology transfer and start-up creation.

Frederic Ratel

Institute of Chemical Research of Catalonia, Spain

testimonial

ASTP brought the right structure and terminology to my knowledge of technology licensing.

René Widmer

ETH Transfer, Switzerland